Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (681-690 of 853) with videos related to

Pageof 86
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
The Biochemical Journal|April 13, 2023
Correction: Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicityDaniel M Foulkes, Keri McLean, Marta Sloniecka, et al.
Investigative Ophthalmology & Visual Science|February 17, 2009
Concentration and bioavailability of ciprofloxacin and teicoplanin in the corneaStephen B Kaye, Timothy Neal, Steven Nicholson, et al.
Lancet (London, England)|September 3, 1988
Carboplatin or cisplatin?A H Calvert, A Horwich, E S Newlands, et al.
Gynecologic Oncology|November 12, 2013
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trialBradley J Monk, Stanley B Kaye, Andrés Poveda, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lungD Cunningham, S W Banham, A H Hutcheon, et al.
Cancer Research|February 1, 1993
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusionD Bissett, A Setanoians, J Cassidy, et al.
BJU International|June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatmentG Pentheroudakis, J S De Bono, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
Science (New York, N.Y.)|September 1, 2018
Response to Comment on "Innovative scattering analysis shows that hydrophobic disordered proteins are expanded in water"Joshua A Riback, Micayla A Bowman, Adam Zmyslowski, et al.
Pageof 86

Showing results (681-690 of 853) with videos related to

Sort By:
Pageof 86
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
The Biochemical Journal|April 13, 2023
Correction: Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicityDaniel M Foulkes, Keri McLean, Marta Sloniecka, et al.
Investigative Ophthalmology & Visual Science|February 17, 2009
Concentration and bioavailability of ciprofloxacin and teicoplanin in the corneaStephen B Kaye, Timothy Neal, Steven Nicholson, et al.
Lancet (London, England)|September 3, 1988
Carboplatin or cisplatin?A H Calvert, A Horwich, E S Newlands, et al.
Gynecologic Oncology|November 12, 2013
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trialBradley J Monk, Stanley B Kaye, Andrés Poveda, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lungD Cunningham, S W Banham, A H Hutcheon, et al.
Cancer Research|February 1, 1993
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusionD Bissett, A Setanoians, J Cassidy, et al.
BJU International|June 26, 2003
Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatmentG Pentheroudakis, J S De Bono, S B Kaye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
Science (New York, N.Y.)|September 1, 2018
Response to Comment on "Innovative scattering analysis shows that hydrophobic disordered proteins are expanded in water"Joshua A Riback, Micayla A Bowman, Adam Zmyslowski, et al.
Pageof 86